Clinical Trial Update: Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) [Phase 3]

View source ↗

Summary

A Phase 3 trial (VIKTORIA-2) is evaluating Gedatolisib as first-line therapy for HR-positive, HER2-negative advanced breast cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Gedatolisib (gedatolisib)

Snippet

Sponsor: Celcuity Inc | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING